Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A small lipidated peptide that inhibits transferrin uptake.

Created on 13 Nov 2026

Authors

Richard Nicosia, Arin Bhattacharjee

Published in

Scientific reports. Volume 16. Pages 33999. Epub Jul 27, 2026.

Abstract

The transferrin receptor (TfR) is a transmembrane glycoprotein that plays a crucial role in iron uptake. TfR is often overexpressed in malignant cancer cells, enabling rapid proliferation. Given the significance of iron uptake in various disease states, blocking transferrin (Tf)-mediated iron uptake could serve as an effective therapeutic strategy. Tf-TfR endocytosis is facilitated by the multimeric AP2 complex through a tyrosine motif on TfR, which is recognized by the AP2 mu subunit. In the present study, fluorescently labeled transferrin was employed to monitor cellular endocytosis in the presence of lipidated decoy peptides containing endocytic motifs that are recognized by the AP2 complex. The results demonstrated that transferrin endocytosis is inhibited when in the presence of a peptide that specifically targets the mu subunit, but not with a peptide that targets the sigma subunit. These findings suggest that Tf-TfR endocytosis can be selectively inhibited through the selective inhibition of the AP2 mu subunit, indicating potential as a novel strategy for inhibiting iron influx in malignant cancer cells.

PMID:
43019116
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement